Our other paper proposed a method validation that applies to the quantification of an analyte isolated by LC followed by offline ana lysis using accelerator MS (AMS) [1] . The validation was aimed at analytical methods in pharmaco kinetic studies where AMS is used to measure drug concentrations arising from a tracer intravenous (i.v.) dose of 14 C-drug given concomitantly with a nonlabeled therapeutic extravascular dose (typically oral). In addition to the quantification of the analyte by AMS, the total drug concentration is also measured, typically by LC-MS. Providing the i.v. dose is sufficiently small and does not significantly add to the total plasma drug concentration, then the LC-MS effectively measures the drug arising from the oral dose. In this way, both oral and i.v. pharmacokinetic data are derived from a single-dose occasion. Such studies determine clearance, volume of distribution and, together with the aforementioned oral data, the absolute bioavailability of a drug in humans, while avoiding issues of nonequivalent clearance, the need for i.v. safety toxicology and often considerable effort in formulation for i.v. administration [2] .
The analytical method is divided into five broad categories:
n Sample preparation from the matrix, which typically involves solvent extraction of the analyte from plasma, isolation of the analyte by LC (e.g., HPLC, UPLC or UHPLC) and fraction collection;
n Isotopic dilution of the isolated fraction;
n Graphitization of the isotopically diluted fraction by oxidation to CO 2 and reduction to graphite;
n Determination of the graphite 14 C: 12 C isotope ratio by AMS, from which the concentration of the analyte is calculated;
n An integral part of determining the drug concentration is the necessity to account for the recovery of the analyte during extraction and LC separation as any losses will result in a proportional error in the calculation of its concentration from the 14 C: 12 C isotope ratio. This article examines one method of determining the recovery of the analyte based on the use of an internal standard.
Calculation of analyte recovery
Determination of the analyte concentration from AMS data is achieved using Equation 1 where K is the amount of drug in the LC fraction, R D An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration
The absolute bioavailability, clearance and volume of distribution of a drug can be investigated by administering a very low dose of the 14 C-drug intravenously along with a therapeutic nonlabeled dose by the extravascular route (typically orally). The total drug concentration is measured by an assay such as LC-MS and the 14 C-drug is measured by accelerator MS (AMS). In another article in this issue, a method validation is proposed where AMS was used as the analytical assay. Part of the validation is to assess the recovery of the analyte being measured as this has a direct impact on its quantification. In this article, a method of internal standardisation is described where the UV response of the nonlabeled analyte, spiked in excess into the matrix being analysed, is used for internal standardization. The method allows for the recovery of analyte to be measured in each individual sample being analysed. It is important to know the recovery of a 14 C-labeled analyte when determining its mass concentration from 14 C: 12 C isotopic ratio data using AMS. A method is reported in this article that utilizes the UV response of the nonlabeled drug for internal standardization, so that the recovery for each individual sample analyzed can be ascertained. is the isotope ratio of the analyte after isotopic dilution, Ø is the amount of isotopic diluent, L is the specific activity of the drug administered and q is the recovery of the analyte [3] .
There are a number of possible methods that could be used to account for analyte recovery (i.e., determination of q in Equation 1). In one such method [4] , a series of control plasma samples were spiked with 14 C-drug over a range of suitable concentrations. The amount spiked defined the true drug concentration of each spiked plasma sample (in the example given here three 14 C-concentrations were used from 0.0311 to 6 dpm/ml, plus a blank [4] ). The spiked plasmas were extracted, the analyte isolated by LC, isotopically diluted and the 14 C: 12 C isotope ratio determined by AMS. The apparent drug concentration was calculated using Equation 1, taking q = 1. These results were plotted against the true drug concentrations and the slope of the resulting line provided an estimate of recovery. Clinical samples were then analyzed and the analyte concentrations were calculated from Equation 1, substituting q with the estimated value for recovery. This method, which was based upon external standardization, provided a value for analyte recovery, which gave a value for q on a per batch basis. If, however, the extraction efficiency varied from sample to sample, then this variability would be reflected as imprecision of the final data. More desirable, is a method that accounts for the recovery of every individual sample analyzed based upon the use of an internal standard. LC-MS uses an internal standard method (albeit for the entire method calibration and not just recovery), which typically employs a stableisotope label (SIL) such as a deuterated ( 2 H), or 13 C form of the analyte. The analyte and SIL-internal standard are then measured separately by the mass spectrometer, distinguished by their different masses. The use of such SIL internal standards, however, do not apply to AMS, as this technique measures a 14 C: 12 C isotope ratio, not the mass of the analyte.
Internal standardization of AMS assays
One alternative approach to using SIL standards (and the one described below), is to use the nonlabeled analyte as the internal standard. The addition of nonlabeled analyte to samples prior to LC separation and AMS ana lysis is routinely undertaken as a means of chromatographically locating the peak of interest during fraction collection. The addition of nonlabeled analyte to the sample does not interfere with the 14 C-analyte measurement as the latter is distinguished by the presence of 14 C. Furthermore, the small amount of 12 C added to the sample from the nonlabeled analyte is insignificant compared with the 12 C in the isotope diluent (Ø in Equation 1) and therefore has no significant effect on the 14 C: 12 C isotope ratio. In addition to using the UV response as a chromatographic marker, quantitation of the UV response can also be used for internal standardization providing the nonlabeled analyte is added in an equal amount to all samples analyzed. Furthermore, the addition of the nonlabeled analyte in relatively high concentrations ameliorates possible effects due to nonspecific binding.
The process of accounting for experimental recovery using a nonlabeled analyte as an internal standard is typically as follows. A series of control plasma samples are spiked with 14 C-drug over a range of suitable concentrations (constituting a set of 'recovery standards'). For reasons explained below, the 14 C-drug used to spike the control plasma should be the same specific activity as that used for dosing the subjects in the clinical study. The true concentration (termed K t ) of the drug in the recovery standards is calculated from the amounts spiked into them. The recovery stand-
The recovery standards are allowed to equilibrate for given periods of time, for example 2, 4, 24 and 48 h (explained below). Following these equilibration times, the internal standard (nonlabeled analyte) is added to the spiked plasma and allowed to equilibrate. The concentration of nonlabeled analyte should be such as to give a high signal-to-noise on LC-UV (typically at least 30:1) but should still be soluble in the relevant solvents. The concentration used should be such that the UV response is clearly within the linear range of the detector. The amount of nonlabeled drug added as an internal standard depends upon the expected concentrations of the drug that arise from the oral dose. Ideally, the signal for the internal standard should be at least 30-fold greater than that arising from the drug already present in the plasma from the oral dose at C max . Initially, the expected C max concentrations can be estimated from other pharmacokinetic data but the total plasma drug concentrations are measured by LC-MS as part of the study (see introduction) and so the actual concentrations are known. If retrospectively, drug
Key Terms
Graphitization: Process of chemical oxidation and reduction that converts carbon in a biological sample to graphite, which is then placed into the accelerator mass spectrometer for analysis.
Clinical sample: Samples (e.g., plasma) taken from subjects on a clinical study after the administration of the test drug.
future science group An AMS method to determine analyte recovery from pharmacokinetic studies | Methodology concentrations from the oral dose are found to contribute to the UV signal for the internal standard then they can be subtracted, based on the concentrations measured by LC-MS. It is recognized that there are limitations to any subtractions and, therefore, ideally the ana lysis should be designed so that sufficient amounts of excess internal standard are added to the plasma samples being analyzed. In addition, there is the option of diluting clinical samples around the C max , which then also dilutes the UV signal of the analyte arising from the oral drug. This, of course, also dilutes the 14 C-drug but typically assay sensitivity is not an issue for AMS ana lysis, particularly in the early phases of the i.v. plasma concentrationtime curve. Once the internal standard has been added and the samples allowed to equilibrate, the plasma samples are then extracted, using an appropriate number of replicates, and the extracts run on LC. The UV response is used to locate the retention time (and hence related fraction) corresponding to the analyte, which is then isotopically diluted, graphitized and the isotope ratio determined by AMS. The UV response is also recorded.
The apparent drug concentration determined by LC followed by AMS is calculated using where K a is the apparent amount of analyte in the fraction without account of recovery, R D is the isotope ratio of the analyte after isotopic dilution, Ø is the amount of isotopic diluent and L is the specific activity of the drug administered. The apparent amount in the fraction (K a ) is compared with the true value (K t ) and the fraction recovered (F r ) calculated by K a /K t . A value for a term called the recovery constant (m) is then calculated from Equation 3, where U is the UV response for the nonlabeled analyte internal standard. The value for F r may vary from sample to sample largely depending upon the variability of the extraction efficiency. Providing however, the internal standard is in equilibrium with the 14 C-drug then the 14 C and nonlabeled drug should both extract to the same efficiency and the value for m should not vary. The reason for determining the value of m over time, as described above, is precisely to ensure that it does indeed remain constant. It should also be kept in mind that since the nonlabeled analyte is added as a constantly equal and excess amount then, in effect, all samples contain the same total mass concentration of analyte and therefore there are minimal concentration-dependent effects in extraction and nonspecific binding [3] . This being the case, the range of concentrations of 14 C-analyte used for the recovery standards can be reduced considerably and as few as two is feasible. This proposal is supported in a study by Simpson. where six concentrations of recovery standards were used to separately calculate the recovery of (R)-and (S)-verapamil following 2D chiral chromatography [5] . The recovery calculated by a linear regression of all six concentrations and for each individual concentration using the method described above, showed no significant difference. It is, however, recommended that at least five replicates are analyzed at each concentration of recovery standard (interestingly, concentration-dependent effects have been reported for the use of an external standard [4] ).
It is important that the extraction properties of the spiked 14 C-drug are analogous to the incurred 14 C-drug and this will only occur once the spiked 14 C is in equilibrium with the matrix. The time taken to achieve this will be compound-dependent and some drugs may take longer to reach equilibrium than others (hence the range of times investigated earlier in this article to allow for equilibration). It may be advantageous, for example, to agitate the recovery standards over time or incubate them at body temperature (37°C) depending upon the stability of the compound being investiagted. The effects of freeze-thaw cycles may also have to be investigated.
Assuming m is shown to be constant over a given period of time, then in order to analyze the clinical samples, an equal and known amount of nonlabeled analyte is added to the samples as an internal standard and allowed to equilibrate for the appropriate time. The internal standard, being the nonlabeled analyte of interest, will also be present in the plasma samples arising from absorbed extravascular dose. It is therefore important to add sufficient internal standard so that the UV response is sufficiently in excess of that from the presence of the drug in the samples. Typically, the concentration of the internal standard should be 30-times that of the drug present at the C max . Each sample is extracted, run on LC and the fraction future science group Bioanalysis (2011) 3(4) corresponding to the retention time of the parent is collected, graphitized and the 14 C: 12 C isotope ratio determined by AMS. In the same way as described above, the UV response is also measured. The recovery of the parent drug for any particular individual sample (q) is given by Equation 4,
The concentration of the analyte in the clinical sample calculated from the AMS data is corrected for recovery by dividing by the value for R on a sample by sample basis, to yield the actual drug concentration (e.g., if recovery for one clinical sample was 100%, then R would be equal to 1. If the recovery of the next clinical sample was 50%, then R would be 0.5).
When using an external standard approach (see previous discussion) it is possible that the value obtained for recovery may vary from batch to batch or over a concentration range. However, when using an internal standard, any batch-tobatch or sample-to-sample variation should not be significant as recovery for each separate sample is taken into account. Indeed if changes in the value of m do occur over the time of the analyzes, this would indicate that something in the system changed and should be investigated. The value of m could change and result in a drift in the apparent recovery if, for example, the UV response changed over time (e.g., UV lamp deterioration). Regular injections of a nonlabeled analyte standard are therefore made periodically to monitor any possible changes in the UV response. Given the importance of the UV response, if more than one LC system is used during sample ana lysis, a value for m should be determined based on each system.
Conclusion
Internal standardization using the UV response of the nonlabeled analyte allows the analyte recovery to be calculated for each individual clinical sample analyzed. The method has been successfully applied to a number of reported studies involving LC isolation of an analyte followed by offline AMS ana lysis [5] [6] [7] [8] . It provides a precise and accurate method of determining q in Equation 1 and is therefore offered as a robust option during method validation of LC followed by AMS when applied to bioana lysis.
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